Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Nov
03
2016
SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that six abstracts highlighting the Company's programs, including an oral presentation on its natural... Read All »
Oct
31
2016
SAN DIEGO, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, November 7, 2016 at 5:... Read All »
Oct
05
2016
Protects Cellular Composition of Lead Immunotherapy Product Candidate ProTmune™ Covers Compositions Generated Using Ex Vivo Modulation to Enhance Stem Cell Properties SAN DIEGO, Oct. 05, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biophar... Read All »
Sep
26
2016
SAN DIEGO, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for ProTmune... Read All »
Sep
07
2016
Unite Cellular Immunotherapy Expertise to Accelerate Clinical Translation of Off-the-Shelf Products Offering Broad Patient Access Collaboration to Use Engineered Pluripotent Cell Lines to Renewably Generate T-Cell Product Candidates Foundation... Read All »
Aug
31
2016
SAN DIEGO, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will be presenting at two upcoming inves... Read All »
Aug
10
2016
SAN DIEGO, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will present at the 2016 Wedbush PacGrow H... Read All »
Aug
08
2016
Opened Patient Enrollment in Phase 1/2 Clinical Trial of ProTmune™ for Prevention of Acute GvHD and CMV Infection IND Filing for Allogeneic Memory-Like NK Cell Cancer Immunotherapy Planned for 2016 Announced $10.3 Million Common Stock Private... Read All »
Aug
08
2016
SAN DIEGO, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has entered into a securities purchase agreement for a private placement with a selec... Read All »
Aug
02
2016
SAN DIEGO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, August 8, 2016 at 5:00... Read All »
Jul
26
2016
Key Patent Covers Renewable Pluripotent Cell Source for Development of Off-the-Shelf NK- and T-Cell Immunotherapies SAN DIEGO, July 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapie... Read All »
Jun
20
2016
SAN DIEGO, June 20, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ProTmune͐... Read All »
Jun
16
2016
SAN DIEGO, June 16, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it will host a Focus Session entitled "Fighting Cancer with Off-the-Shelf iPSC Immunother... Read All »
Jun
11
2016
One-time Administration of Programmed Cells Demonstrates Durable Disease Correction in Type 1 Diabetes Mouse Model ToleraCyte™ Product Candidate Exhibits Enhanced Trafficking to the Pancreas and Potent Regulation of Autoreactive T Cells in Preclinical Testing... Read All »
May
17
2016
SAN DIEGO, May 17, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Chris M. Storgard, M.D. has joined the Company as its Chief Medical Officer.  Dr. Storgard i... Read All »
= add release to Briefcase